Paratek Pharmaceuticals Broadens Clinical Profile of NUZYRA™ (Omadacycline) with New ECCMID 2019 Data Presentations

    NEXT STORY
    NILE Study Results Demonstrating Guardant360’s High Concordance to Tissue Testing in Advanced NSCLC Published in Clinical Cancer Research
    PREV STORY
    Sprint Through Real-Time Promo Review
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Results from Influenza Challenge Study Published in Lancet Infectious Diseases

    author_avatar
    NASDAQ Market News

    Human Microbiome Therapeutics Market Size Worth USD 1,098.4 Million by 2027 | Rising Government Initiatives In Microbiome Research Projects And Increasing Drug-Related Side Effects Are Driving The Industry Growth, says Emergen Research

    author_avatar
    NASDAQ Market News

    European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma

    author_avatar
    NASDAQ Market News